Based on in vivo mice experiments using human serum albumin-conjugated soluble EphB4, it was confirmed that EphB4 could serve as a potential therapeutic target in pancreatic ductal adenocarcinoma and further research is necessary to prove its efficacy in the treatment of pancreatic cancer patients. This evidence concerns the gene ALB and pancreatic ductal adenocarcinoma.